Company news

Share this article:

Merck has agreed to purchase San Diego-based NovaCardia, a privately held clinical-stage pharmaceutical company focused on cardiovascular diseases, for $350 million plus the amount of cash on hand at the time of closing. Merck will pay for NovaCardia in Merck stock, to be valued based on the average closing stock price on the five days prior to closing of the deal. NovaCardia's lead product candidate, KW-3902, is being studied in late-stage clinical trials in patients with acute congestive heart failure. In March, NovaCardia filed with the Securities and Exchange Commission to raise up to $86.3 million in an initial public offering. 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.